Observational studyBMJ open2024

Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals.

Jean-Matthieu L'Orphelin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.